NCT03844256View on ClinicalTrials.gov

A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2026

Conditions
Urinary Bladder CancerInvasive Bladder Cancer
Interventions
COMBINATION_PRODUCT

nivolumab 480mg

Immuno-chemoradiotherapy

COMBINATION_PRODUCT

nivolumab 3mg/kg, ipilimumab 1mg/kg

Immuno-chemoradiotherapy

COMBINATION_PRODUCT

nivolumab 1mg/kg, ipilimumab 3mg/kg

Immuno-chemoradiotherapy

Trial Locations (3)

1081 HV

RECRUITING

Amsterdam UMC, VUmc, Amsterdam

1105 AZ

RECRUITING

Amsterdam UMC, AMC, Amsterdam

Unknown

RECRUITING

LUMC, Leiden

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER